Full-Time

SAP S/4HANA Data Transformation Manager PP & QM

Lonza

Lonza

10,001+ employees

Global life sciences contract manufacturer

No salary listed

Hyderabad, Telangana, India

In Person

Category
Data & Analytics (1)
Required Skills
Machine Learning

Get referred to Lonza

See people who can refer or advise you

Requirements
  • Proven experience in SAP S/4HANA PP & QM, Data Management, Data Migration and/or Digital Transformation projects and/or consulting.
  • Experience with SAP Master Data Governance (MDG) and/or other Data Management or Data Migration tools.
  • Passion for Data, Digital Transformation and innovative new technologies
  • Deep understanding of PP & QM data model and objects in S/4HANA.
  • Strong analytical and problem-solving skills, with a focus on attention to detail.
  • Project management and organizational skills, with experience in preparing and delivering training and workshops.
  • Strong communication skills, with the ability to work effectively with technical and non-technical stakeholders.
Responsibilities
  • Support Lonza’s global CDMO sites in achieving data readiness for the S/4HANA deployment by preparing, orchestrating the finalization of all data preparation activities within the data domains of S/4HANA Production Planning (PP) & Quality Management (QM). This concerns mainly data models and objects (i.e. material master, BOMs, etc.) linked to business processes Plan-to-Make (P2M), Procure-to-Pay (P2P) and Order-to-Cash (O2C).
  • Establish and develop standardized best-in class delivery plans, processes, tools and templates to support data preparation activities and continuously improve them.
  • Mobilize local data owners / key users and facilitate their enablement by preparing and delivering onboarding, training, alignment meetings and workshops.
  • Closely coordinate with the 3rd party integration partner to support the finalization of key deliverables, such as data designs, mappings, construct files, transformations etc. as well as achieving formal sign-off from data owners and other stakeholders.
  • Orchestrate multiple integrated Data Harmonization initiatives together with other Data Domains towards their finalization, approval to be built into Data Migration
  • Support Lonza’s global CDMO sites end-to-end during S/4HANA deployment with all data-related activities, mainly Data Migration, cutover and post-go live support.
  • Orchestrate and coordinate migration activities between the 3rd party integration partner, the Nexus project teams and data owners / key users. Support migration activities such as testing, mock loads incl. validation, defect fixing in line with the migration plan. Identify and document issues promptly and drive timely resolution.
  • Ensure Project & Quality-relevant documentation requirements are adhered to.
  • Drive innovation by identifying opportunities for automation and adopting new technologies such as AI and Machine Learning.
  • Support the rollout of the SAP Master Data Governance (MDG) system for Master Data Management along with the global S/4HANA deployments.
  • Coordinate and support central transactional Master Data Management teams with training, handover during deployments to facilitate strong data governance and high data quality effective from Day +1 after go-live.
  • Identify, manage and coordinate change requests concerning the S/4HANA data model and/or data management processes as well as SAP MDG workflows and data quality rulesets or exceptions such as mass data loads. Ensure alignment and formal approval by Nexus Data Information Architects to ensure the integrity of the S/4HANA process template including its data model and data designs.
  • Monitor and resolve data-management related issues and service ticket management. Ensure disruptions and issues are assigned and addressed promptly.
  • Formalize all detailed activities into a comprehensive deployment toolkit incorporating a structured and disciplined approach, to enable standardized, repeatable process execution during future deployments with consistent quality.
  • Monitor quality of work by performing reviews against standards and follow-ups.
  • Ensure adhere to plan by continuous progress tracking and reporting.
  • Proactively identify and monitor risks and issues and report them to project management. Define and implement corrective actions as needed.
  • Ensure compliant documentation of all data activities is established in line with program requirements.
  • Provide training and support to data owners to support consistent execution.
  • Document lessons learned and contributed to continuous improvement efforts.
  • Coordinate all activities closely with the 3rd party integration partner, internal Nexus Data, IT/Tech and Business Process teams to ensure continuous alignment of all activities with program planning and the Data Migration and Harmonization Strategy.
  • Ensure continuous alignment with Data & Information Architects and continuous improvement of operational data management.

Lonza is a global provider of development and manufacturing services for the pharmaceutical, biotechnology, and nutrition sectors. It supports clients from early development through to commercial production, offering integrated processes such as process development, GMP manufacturing, formulation, fill-finish, and quality assurance to bring medicines and nutrition products to market. Lonza’s model is built on end-to-end CDMO capabilities, enabling companies to move from concept to scalable, compliant production with reliable supply chains. What sets Lonza apart is its long history and global footprint, combining decades of experience across chemistry, biology, and nutrition with a broad, end-to-end service network that supports projects from discovery to commercialization. The company aims to be a trusted, long-term partner in life sciences by helping customers efficiently develop and manufacture their products at scale while maintaining strict regulatory and quality standards.

Company Size

10,001+

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1897

Get referred to Lonza

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 16% constant-currency, with core EBITDA margin reaching 34.8%.
  • Lonza raised 2026 margin guidance to 33-34% and announced a CHF 500 million buyback.
  • New Engitix ADC licensing and RaMP media launch expand high-value pipeline and customer lock-in.

What critics are saying

  • ToolGen's Dutch and Hague patent suits threaten CASGEVY revenues and court injunctions in 2026.
  • Vacaville's 2026 shutdown for readiness work creates execution risk and temporary revenue phasing.
  • Siegfried's May 2026 Noramco acquisition overtook Lonza in HPAPI leadership, intensifying pricing pressure.

What makes Lonza unique

  • Lonza's 2026 pure-play CDMO transformation centers on integrated biologics, ADCs, and HPAPIs.
  • Visp and Stein expansions build sticky end-to-end manufacturing, from payload-linkers to aseptic fill-finish.
  • Vacaville plus global media network gives Lonza rare commercial scale and early-development continuity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

17%

1 year growth

17%

2 year growth

17%
Ochre Digi Media Pvt. Ltd.
Aug 17th, 2026
Lonza launches rapid custom Media Prototyping Service to accelerate early bioprocess development.

Lonza launches rapid custom Media Prototyping Service to accelerate early bioprocess development. Monday, August 17, 2026 Lonza, the world's leading contract development and manufacturing organization (CDMO), today announced its Rapid Media Prototyping Service (RaMP), giving biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation and early development. With the possibility to send non-GMP powder batches from 1-10 kg and liquid batches from 1-100 L produced within 10 working days, the service helps scientists accelerate timelines, generate critical process data and prepare for GMP manufacturing. RaMP addresses common early development challenges, including long lead times for custom prototype media, limited small-batch manufacturing options and the need to align early formulation work with future manufacturing requirements. RaMP is part of Lonza's end-to-end custom media and buffer solutions offering, supporting customers from media development and screening through non-GMP prototyping and commercial GMP manufacturing. By linking early formulation work with long-term scalability, the service helps simplify development and support manufacturing readiness. Omar Wahab, Vice President, Head of Bioprocessing, Lonza, commented: "Development teams are under pressure to generate data quickly, make informed process decisions and keep programs moving toward the clinic. RaMP gives customers the possibility of rapid access to custom media in the quantities they need, when they need it. By connecting early screening and process confirmation with future GMP requirements, we help reduce scale-up risk, simplify technology transfer and support a more efficient path to commercialization." Delivered through Lonza's global media development and manufacturing network, RaMP combines rapid turnaround, flexible batch sizes and specialized expertise to help customers advance development with greater confidence while preparing for scale-up and GMP manufacturing. Further information about Lonza's custom media capabilities, including development, prototyping and manufacturing support, is available on the Lonza website: Custom media and buffer solutions | Lonza. Lonza Contact Details [email protected] About Lonza Lonza is the world's leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across five continents, Lonza's global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing. Its company generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026. Find out more at www.lonza.com. Disclaimer Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this media advisory due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory. All trademarks belong to Lonza, and are registered in the USA, EU and/or CH, or used in common law, or belong to their respective third-party owners and are used for informational purposes only.

BioStrata
Aug 17th, 2026
Lonza launches rapid custom Media Prototyping Service to accelerate early bioprocess development.

Lonza launches rapid custom Media Prototyping Service to accelerate early bioprocess development. August 17, 2026 * Rapid access to custom liquid and powder media helps scientists move from formulation design to process decisions faster, while supporting a clearer path to future GMP manufacturing * Flexible non-GMP batch sizes and target turnaround times of up to 10 working days support early screening, process confirmation and development activities * Integrated custom media and buffer capabilities help customers reduce development complexity and keep future scale-up requirements in focus Lonza, the world's leading contract development and manufacturing organization (CDMO), today announced its Rapid Media Prototyping Service (RaMP), giving biopharmaceutical companies faster access to custom liquid and powder media for screening, process confirmation and early development. With the possibility to send non-GMP powder batches from 1-10 kg and liquid batches from 1-100 L produced within 10 working days, the service helps scientists accelerate timelines, generate critical process data and prepare for GMP manufacturing. RaMP addresses common early development challenges, including long lead times for custom prototype media, limited small-batch manufacturing options and the need to align early formulation work with future manufacturing requirements. RaMP is part of Lonza's end-to-end custom media and buffer solutions offering, supporting customers from media development and screening through non-GMP prototyping and commercial GMP manufacturing. By linking early formulation work with long-term scalability, the service helps simplify development and support manufacturing readiness. Omar Wahab, Vice President, Head of Bioprocessing, Lonza, commented: "Development teams are under pressure to generate data quickly, make informed process decisions and keep programs moving toward the clinic. RaMP gives customers the possibility of rapid access to custom media in the quantities they need, when they need it. By connecting early screening and process confirmation with future GMP requirements, we help reduce scale-up risk, simplify technology transfer and support a more efficient path to commercialization." Delivered through Lonza's global media development and manufacturing network, RaMP combines rapid turnaround, flexible batch sizes and specialized expertise to help customers advance development with greater confidence while preparing for scale-up and GMP manufacturing. Further information about Lonza's custom media capabilities, including development, prototyping and manufacturing support, is available on the Lonza website: Custom media and buffer solutions | Lonza Browse more news Recent releases

Samedan Ltd
Jul 28th, 2026
Lonza and Engitix partner to develop next-generation antibody-drug conjugates.

Lonza and Engitix partner to develop next-generation antibody-drug conjugates. Lonza and Engitix have entered into a licensing agreement to support the development of antibody-drug conjugates (ADCs), combining Engitix's extracellular matrix (ECM)-based discovery platform with Lonza's conjugation and linker-payload technologies. Under the agreement, Engitix will license Lonza's ADC technology platform for a single therapeutic target, including the company's SYNtecan E linker-payload technology together with GlycoConnect and HydraSpace platforms. The collaboration aims to develop targeted therapeutics by combining Engitix's approach to identifying disease-associated extracellular matrix targets with established ADC technologies designed to selectively deliver potent therapeutic payloads. ADCs have traditionally targeted proteins on the surface of tumour cells. Engitix's proprietary human ECM platform instead focuses on components of the extracellular matrix, offering an alternative strategy for identifying therapeutic targets in oncology and other diseases characterised by pathological tissue remodelling. Under the terms of the agreement, Lonza will receive upfront, clinical, regulatory and commercial milestone payments, together with royalties on future product sales. The company will manufacture components related to its proprietary technologies, while Engitix will be responsible for research, development, manufacturing and commercialisation of resulting ADC candidates. Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis at Lonza, said: "By combining our ADC development and manufacturing expertise with Engitix's unique ECM-based discovery platform, we aim to advance next-generation ADCs and unlock new possibilities in targeted therapies for patients." Engitix said the agreement supports its strategy to build a pipeline of precision therapeutics targeting fibrosis, oncology and other diseases driven by pathological tissue remodelling, while expanding the application of extracellular matrix biology to drug development.

The Pharma Letter
Jul 25th, 2026
Siegfried and Lonza lead four-way CDMO race in outsourced HPAPI.

Siegfried and Lonza lead four-way CDMO race in outsourced HPAPI. 24 July 2026 Known for their low-dose therapeutic efficacy and high target affinity, high-potency active pharmaceutical ingredients (HPAPIs) are in high demand by biopharma companies, which often outsource their production. Approximately 41% of innovator and biosimilar HPAPIs come from contract development and manufacturing organizations (CDMOs). With strategic acquisitions and expansions of HPAPI facilities reshaping the HPAPI outsourcing market, four CDMOs - Lonza (LONN: SIX), Siegfried, Aspen, and Veranova - are competing for leadership, with two of them, Lonza and Siegfried, pulling out in front, according to pharma intelligence firm GlobalData. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 6 July 2026 11 June 2026 16 June 2026 Company news directory. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 24 July 2026 Company spotlight. A Santa Cruz, California-based biotechnology company developing orally delivered macrocyclic peptides that combine biologic-level potency with small-molecule drug-like properties to engage previously undruggable targets across cardiovascular and immunology. More features in pharmaceutical. 24 July 2026

Yahoo Finance
Jul 22nd, 2026
Lonza reports $3.8B revenue with 16% growth, upgrades EBITDA margin outlook to 33-34%

Lonza Group reported strong financial results for the first half of 2026, with revenue reaching CHF3.4 billion and core EBITDA of CHF1.2 billion, representing a margin of 34.8%. The Swiss pharmaceutical company achieved 16% sales growth in constant exchange rates compared to the same period in 2025. Free cash flow improved by CHF300 million year-on-year to CHF426 million. All three business segments showed robust performance: Integrated Biologics grew 10%, Advanced Synthesis jumped 27.7%, and Specialized Modalities increased 22.6%. The company upgraded its full-year core EBITDA margin outlook to 33%-34% whilst reconfirming sales growth expectations of 11%-12%. Return on invested capital rose nearly 3 percentage points to 13.2% on an annualised basis. However, Lonza faces headwinds including a 5-percentage-point impact from foreign exchange fluctuations and anticipated slower growth in the second half due to higher prior-year comparisons.